Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Wall Street's top stories at midday » 12:18
05/12/21
05/12
12:18
05/12/21
12:18
DPZ

Domino's Pizza

$425.13 /

+2.43 (+0.57%)

, SBUX

Starbucks

$110.15 /

-2.93 (-2.59%)

, EA

Electronic Arts

$139.24 /

-2.09 (-1.48%)

, WEN

Wendy's

$22.56 /

-0.24 (-1.05%)

, AJG

Arthur J. Gallagher

$146.06 /

-2.42 (-1.63%)

, AON

Aon plc

$251.63 /

-2.36 (-0.93%)

, WLTW

Willis Towers Watson

$263.18 /

-1.44 (-0.54%)

, PSTH

Pershing Square Tontine Holdings

$23.75 /

+1.12 (+4.95%)

, UPST

Upstart

$95.92 /

+6.58 (+7.37%)

, FUBO

FuboTV

$19.38 /

+1.83 (+10.43%)

, AMRN

Amarin

$4.43 /

-0.195 (-4.22%)

, ARRY

Array Technologies

$16.51 /

-8.45 (-33.85%)

, SLQT

SelectQuote

$22.00 /

-5.38 (-19.65%)

, LITE

Lumentum

$68.62 /

-13.6 (-16.54%)

Equity futures extended…

ShowHide Related Items >><<
WLTW Willis Towers Watson
$263.18 /

-1.44 (-0.54%)

WEN Wendy's
$22.56 /

-0.24 (-1.05%)

UPST Upstart
$95.92 /

+6.58 (+7.37%)

SLQT SelectQuote
$22.00 /

-5.38 (-19.65%)

SBUX Starbucks
$110.15 /

-2.93 (-2.59%)

PSTH Pershing Square Tontine Holdings
$23.75 /

+1.12 (+4.95%)

LITE Lumentum
$68.62 /

-13.6 (-16.54%)

FUBO FuboTV
$19.38 /

+1.83 (+10.43%)

EA Electronic Arts
$139.24 /

-2.09 (-1.48%)

DPZ Domino's Pizza
$425.13 /

+2.43 (+0.57%)

ARRY Array Technologies
$16.51 /

-8.45 (-33.85%)

AON Aon plc
$251.63 /

-2.36 (-0.93%)

AMRN Amarin
$4.43 /

-0.195 (-4.22%)

AJG Arthur J. Gallagher
$146.06 /

-2.42 (-1.63%)

DPZ Domino's Pizza
$425.13 /

+2.43 (+0.57%)

05/04/21 Northcoast
Domino's Pizza downgraded to Neutral from Buy at Northcoast
04/30/21 Stephens
Domino's Pizza price target raised to $405 from $360 at Stephens
04/30/21 RBC Capital
Domino's Pizza price target raised to $466 from $446 at RBC Capital
04/30/21 Credit Suisse
Domino's Pizza price target raised to $460 from $425 at Credit Suisse
SBUX Starbucks
$110.15 /

-2.93 (-2.59%)

04/28/21 Morgan Stanley
Starbucks price target raised to $120 from $110 at Morgan Stanley
04/28/21 MKM Partners
Starbucks price target raised to $125 from $117 at MKM Partners
04/28/21 Wedbush
Starbucks price target raised to $132 from $124 at Wedbush
04/28/21 Credit Suisse
Starbucks price target raised to $125 from $116 at Credit Suisse
EA Electronic Arts
$139.24 /

-2.09 (-1.48%)

05/12/21 Benchmark
Electronic Arts price target raised to $181 from $177 at Benchmark
05/12/21 Barclays
Electronic Arts price target lowered to $142 from $145 at Barclays
05/10/21 Credit Suisse
Electronic Arts price target raised to $167 from $160 at Credit Suisse
04/22/21 Jefferies
Jefferies upgrades Electronic Arts to Buy, sees sentiment as 'too negative'
WEN Wendy's
$22.56 /

-0.24 (-1.05%)

04/12/21 JPMorgan
Wendy's price target raised to $27 from $25 at JPMorgan
03/24/21 Wedbush
Wendy's added to Best Ideas List at Wedbush
03/22/21
Fly Intel: Top five analyst downgrades
03/22/21 Argus
Wendy's cut to Hold at Argus on weak traffic, high debt
AJG Arthur J. Gallagher
$146.06 /

-2.42 (-1.63%)

05/03/21 Raymond James
Arthur J. Gallagher price target raised to $165 from $155 at Raymond James
04/30/21 Truist
Arthur J. Gallagher price target raised to $165 from $143 at Truist
04/30/21 RBC Capital
Arthur J. Gallagher price target raised to $142 from $124 at RBC Capital
03/18/21 Deutsche Bank
Arthur J. Gallagher downgraded to Hold from Buy at Deutsche Bank
AON Aon plc
$251.63 /

-2.36 (-0.93%)

05/03/21 Wells Fargo
Aon plc price target raised to $287 from $275 at Wells Fargo
05/03/21 JPMorgan
Aon plc price target raised to $249 from $241 at JPMorgan
05/03/21 Deutsche Bank
Aon plc price target raised to $245 from $205 at Deutsche Bank
04/12/21 JPMorgan
Aon plc price target raised to $241 from $228 at JPMorgan
WLTW Willis Towers Watson
$263.18 /

-1.44 (-0.54%)

05/04/21 Deutsche Bank
Willis Towers Watson price target raised to $265 from $221 at Deutsche Bank
02/11/21
Fly Intel: Top five analyst upgrades
02/11/21 Raymond James
Willis Tower Watson upgraded to Strong Buy from Outperform at Raymond James
PSTH Pershing Square Tontine Holdings
$23.75 /

+1.12 (+4.95%)

UPST Upstart
$95.92 /

+6.58 (+7.37%)

05/12/21 JMP Securities
Upstart price target raised to $149 from $111 at JMP Securities
05/12/21 Piper Sandler
Upstart price target raised to $152 from $143 at Piper Sandler
04/27/21
Fly Intel: Top five analyst initiations
04/27/21 Piper Sandler
Upstart initiated with an Overweight at Piper Sandler
FUBO FuboTV
$19.38 /

+1.83 (+10.43%)

05/12/21 Needham
FuboTV again exceeded commitments and guided metrics, says Needham
05/12/21 Evercore ISI
FuboTV's 'clean beat and raise' Q1 report a 'home run,' says Evercore ISI
04/05/21 Evercore ISI
FuboTV assumed with an Outperform at Evercore ISI
03/29/21 Needham
Needham lays out 'bull case' on 'inexpensive' FuboTV shares
AMRN Amarin
$4.43 /

-0.195 (-4.22%)

05/12/21
Fly Intel: Top five analyst downgrades
05/12/21 Goldman Sachs
Amarin downgraded to Sell from Neutral at Goldman Sachs
04/29/21 Piper Sandler
Piper continues to see 'immense market opportunity' for Amarin in EU
04/12/21 Piper Sandler
New CEO at Amarin to facilitate continued growth, says Piper Sandler
ARRY Array Technologies
$16.51 /

-8.45 (-33.85%)

05/12/21 Piper Sandler
Array Technologies downgraded to Neutral from Overweight at Piper Sandler
05/12/21 Barclays
Array Technologies downgraded to Underweight from Overweight at Barclays
05/12/21 Roth Capital
Array Technologies downgraded to Neutral from Buy at Roth Capital
04/22/21 Barclays
Shoals Technologies downgraded to Equal Weight from Overweight at Barclays
SLQT SelectQuote
$22.00 /

-5.38 (-19.65%)

05/12/21 Piper Sandler
SelectQuote should be bought on any guidance selloff, says Piper Sandler
04/06/21 Piper Sandler
SelectQuote assumed with an Overweight at Piper Sandler
03/25/21
Fly Intel: Top five analyst initiations
03/25/21 Goldman Sachs
SelectQuote initiated with a Buy at Goldman Sachs
LITE Lumentum
$68.62 /

-13.6 (-16.54%)

03/26/21 Northland
NeoPhotonics deal 'makes more sense than ever' for Lumentum, says Northland
03/26/21 B. Riley
II-VI upgraded to Buy from Neutral at B. Riley Securities
03/26/21 Raymond James
Lumentum upgraded to Strong Buy from Outperform at Raymond James
03/18/21
Fly Intel: Top five analyst downgrades
WLTW Willis Towers Watson
$263.18 /

-1.44 (-0.54%)

WEN Wendy's
$22.56 /

-0.24 (-1.05%)

UPST Upstart
$95.92 /

+6.58 (+7.37%)

SLQT SelectQuote
$22.00 /

-5.38 (-19.65%)

SBUX Starbucks
$110.15 /

-2.93 (-2.59%)

LITE Lumentum
$68.62 /

-13.6 (-16.54%)

FUBO FuboTV
$19.38 /

+1.83 (+10.43%)

EA Electronic Arts
$139.24 /

-2.09 (-1.48%)

DPZ Domino's Pizza
$425.13 /

+2.43 (+0.57%)

ARRY Array Technologies
$16.51 /

-8.45 (-33.85%)

AON Aon plc
$251.63 /

-2.36 (-0.93%)

AMRN Amarin
$4.43 /

-0.195 (-4.22%)

AJG Arthur J. Gallagher
$146.06 /

-2.42 (-1.63%)

  • 13
    May
  • 09
    Apr
  • 19
    Mar
  • 04
    Mar
  • 30
    Dec
  • 16
    Dec
  • 03
    Dec
  • 15
    Oct
  • 08
    Oct
  • 22
    Jul
  • 21
    May
WEN Wendy's
$22.56 /

-0.24 (-1.05%)

SBUX Starbucks
$110.15 /

-2.93 (-2.59%)

LITE Lumentum
$68.62 /

-13.6 (-16.54%)

EA Electronic Arts
$139.24 /

-2.09 (-1.48%)

AON Aon plc
$251.63 /

-2.36 (-0.93%)

WEN Wendy's
$22.56 /

-0.24 (-1.05%)

UPST Upstart
$95.92 /

+6.58 (+7.37%)

SLQT SelectQuote
$22.00 /

-5.38 (-19.65%)

SBUX Starbucks
$110.15 /

-2.93 (-2.59%)

PSTH Pershing Square Tontine Holdings
$23.75 /

+1.12 (+4.95%)

LITE Lumentum
$68.62 /

-13.6 (-16.54%)

FUBO FuboTV
$19.38 /

+1.83 (+10.43%)

EA Electronic Arts
$139.24 /

-2.09 (-1.48%)

DPZ Domino's Pizza
$425.13 /

+2.43 (+0.57%)

ARRY Array Technologies
$16.51 /

-8.45 (-33.85%)

AMRN Amarin
$4.43 /

-0.195 (-4.22%)

AJG Arthur J. Gallagher
$146.06 /

-2.42 (-1.63%)

WEN Wendy's
$22.56 /

-0.24 (-1.05%)

UPST Upstart
$95.92 /

+6.58 (+7.37%)

SLQT SelectQuote
$22.00 /

-5.38 (-19.65%)

SBUX Starbucks
$110.15 /

-2.93 (-2.59%)

PSTH Pershing Square Tontine Holdings
$23.75 /

+1.12 (+4.95%)

LITE Lumentum
$68.62 /

-13.6 (-16.54%)

FUBO FuboTV
$19.38 /

+1.83 (+10.43%)

EA Electronic Arts
$139.24 /

-2.09 (-1.48%)

AON Aon plc
$251.63 /

-2.36 (-0.93%)

AMRN Amarin
$4.43 /

-0.195 (-4.22%)

Downgrade
Fly Intel: Top five analyst downgrades » 09:56
05/12/21
05/12
09:56
05/12/21
09:56
NVAX

Novavax

$135.00 /

-3.16 (-2.29%)

, DG

Dollar General

$210.70 /

-3.255 (-1.52%)

, GO

Grocery Outlet

$35.54 /

-5.01 (-12.36%)

, JAMF

Jamf Holding

$30.70 /

-0.93 (-2.94%)

, AMRN

Amarin

$4.42 /

-0.2 (-4.33%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Novavax (NVAX) downgraded to Neutral from Overweight at JPMorgan with analyst Eric Joseph saying there were "several disappointing updates" on the recent earnings call, the most troubling is the "clear challenge" the company still faces in manufacturing its vaccine candidate at large scale. 2. Dollar General (DG) downgraded to Sector Perform from Outperform at RBC Capital with analyst Scot Ciccarelli noting that the company continues to execute at a high level, but an improving employment macro environment could reduce the trade-down activity even as rising food and gas prices pressure their existing customer. 3. Grocery Outlet (GO) downgraded to Hold from Buy at Deutsche Bank and downgraded to Hold from Buy at Craig-Hallum. 4. Jamf Holding (JAMF) downgraded to Neutral from Buy at Goldman Sachs with analyst Rod Hall saying the company reported "solid" Q1 results but the implied second half of 2021 guidance is 2% below forecasts due to uncertainties around the sustainability of educational tailwinds and the pickup of commercial demand. 5. Amarin (AMRN) downgraded to Sell from Neutral at Goldman Sachs with analyst Paul Choi saying generic entrants in the U.S. will limit Vascepa's growth ahead of the European launch. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link

ShowHide Related Items >><<
NVAX Novavax
$135.00 /

-3.16 (-2.29%)

JAMF Jamf Holding
$30.70 /

-0.93 (-2.94%)

GO Grocery Outlet
$35.54 /

-5.01 (-12.36%)

DG Dollar General
$210.70 /

-3.255 (-1.52%)

AMRN Amarin
$4.42 /

-0.2 (-4.33%)

NVAX Novavax
$135.00 /

-3.16 (-2.29%)

05/12/21 B. Riley
Novavax price target lowered to $286 from $365 at B. Riley
05/12/21 Cantor Fitzgerald
Novavax price target lowered to $217 from $338 at Cantor Fitzgerald
05/12/21 H.C. Wainwright
Novavax price target lowered to $294 from $317 at H.C. Wainwright
05/12/21 JPMorgan
Novavax downgraded to Neutral from Overweight at JPMorgan
DG Dollar General
$210.70 /

-3.255 (-1.52%)

05/12/21 RBC Capital
RBC Capital cuts Dollar General to Sector Perform on improving employment
05/12/21 RBC Capital
Dollar General downgraded to Sector Perform from Outperform at RBC Capital
05/04/21
Fly Intel: Top five analyst downgrades
05/04/21 KeyBanc
Dollar General downgraded to Sector Weight from Overweight at KeyBanc
GO Grocery Outlet
$35.54 /

-5.01 (-12.36%)

05/12/21 Craig-Hallum
Grocery Outlet downgraded to Hold at Craig-Hallum
05/12/21 Craig-Hallum
Grocery Outlet downgraded to Hold from Buy at Craig-Hallum
05/12/21 Deutsche Bank
Grocery Outlet downgraded on market share concerns at Deutsche Bank
05/12/21 Deutsche Bank
Grocery Outlet downgraded to Hold from Buy at Deutsche Bank
JAMF Jamf Holding
$30.70 /

-0.93 (-2.94%)

05/12/21 Goldman Sachs
Jamf Holding downgraded to Neutral from Buy at Goldman Sachs
05/12/21 RBC Capital
Jamf Holding price target lowered to $45 from $49 at RBC Capital
05/12/21 Canaccord
Jamf Holding too cheap given execution record, says Canaccord
05/12/21 Mizuho
Jamf Holding price target lowered to $42 from $45 at Mizuho
AMRN Amarin
$4.42 /

-0.2 (-4.33%)

05/12/21 Goldman Sachs
Amarin downgraded to Sell from Neutral at Goldman Sachs
04/29/21 Piper Sandler
Piper continues to see 'immense market opportunity' for Amarin in EU
04/12/21 Piper Sandler
New CEO at Amarin to facilitate continued growth, says Piper Sandler
04/06/21 Piper Sandler
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
NVAX Novavax
$135.00 /

-3.16 (-2.29%)

JAMF Jamf Holding
$30.70 /

-0.93 (-2.94%)

GO Grocery Outlet
$35.54 /

-5.01 (-12.36%)

DG Dollar General
$210.70 /

-3.255 (-1.52%)

AMRN Amarin
$4.42 /

-0.2 (-4.33%)

  • 19
    Nov
  • 13
    Aug
  • 22
    Jul
NVAX Novavax
$135.00 /

-3.16 (-2.29%)

NVAX Novavax
$135.00 /

-3.16 (-2.29%)

JAMF Jamf Holding
$30.70 /

-0.93 (-2.94%)

GO Grocery Outlet
$35.54 /

-5.01 (-12.36%)

DG Dollar General
$210.70 /

-3.255 (-1.52%)

AMRN Amarin
$4.42 /

-0.2 (-4.33%)

NVAX Novavax
$135.00 /

-3.16 (-2.29%)

DG Dollar General
$210.70 /

-3.255 (-1.52%)

AMRN Amarin
$4.42 /

-0.2 (-4.33%)

On The Fly
Fly Intel: Pre-market Movers » 08:59
05/12/21
05/12
08:59
05/12/21
08:59
LHDX

Lucira Health

$5.10 /

+0.555 (+12.21%)

, EYES

Second Sight

$4.97 /

-0.185 (-3.59%)

, DT

Dynatrace

$45.44 /

+0.035 (+0.08%)

, WEN

Wendy's

$22.81 /

+0.08 (+0.35%)

, FUBO

FuboTV

$17.55 /

+1.19 (+7.27%)

, EA

Electronic Arts

$141.30 /

+0.62 (+0.44%)

, LITE

Lumentum

$82.24 /

+1.335 (+1.65%)

, TSEM

Tower Semiconductor

$27.61 /

+0.01 (+0.04%)

, WWW

Wolverine World Wide

$42.75 /

-0.5 (-1.16%)

, LMND

Lemonade

$73.89 /

+2.82 (+3.97%)

, ARRY

Array Technologies

$24.96 /

+0.04 (+0.16%)

, GO

Grocery Outlet

$40.62 /

-0.7 (-1.69%)

, AMRN

Amarin

$4.62 /

+0.02 (+0.43%)

Check out this morning's…

ShowHide Related Items >><<
WEN Wendy's
$22.81 /

+0.08 (+0.35%)

TSEM Tower Semiconductor
$27.61 /

+0.01 (+0.04%)

LMND Lemonade
$73.89 /

+2.82 (+3.97%)

LITE Lumentum
$82.24 /

+1.335 (+1.65%)

LHDX Lucira Health
$5.10 /

+0.555 (+12.21%)

GO Grocery Outlet
$40.62 /

-0.7 (-1.69%)

FUBO FuboTV
$17.55 /

+1.19 (+7.27%)

EYES Second Sight
$4.97 /

-0.185 (-3.59%)

EA Electronic Arts
$141.30 /

+0.62 (+0.44%)

DT Dynatrace
$45.44 /

+0.035 (+0.08%)

ARRY Array Technologies
$24.96 /

+0.04 (+0.16%)

AMRN Amarin
$4.62 /

+0.02 (+0.43%)

LHDX Lucira Health
$5.10 /

+0.555 (+12.21%)

05/04/21 William Blair
William Blair downgrades Lucira Health on slowing Covid testing volumes
05/04/21 William Blair
Lucira Health downgraded to Market Perform from Outperform at William Blair
04/13/21
Fly Intel: Top five analyst downgrades
04/13/21 BofA
Lucira Health downgraded to Underperform from Buy at BofA
EYES Second Sight
$4.97 /

-0.185 (-3.59%)

DT Dynatrace
$45.44 /

+0.035 (+0.08%)

03/22/21 Goldman Sachs
Dynatrace initiated with a Buy at Goldman Sachs
03/03/21 Citi
Dynatrace assumed with a Buy at Citi
02/04/21
Dynatrace price target raised to $50 from $40 at Loop Capital
02/04/21
Dynatrace price target raised to $65 from $50 at DA Davidson
WEN Wendy's
$22.81 /

+0.08 (+0.35%)

04/12/21 JPMorgan
Wendy's price target raised to $27 from $25 at JPMorgan
03/24/21 Wedbush
Wendy's added to Best Ideas List at Wedbush
03/22/21
Fly Intel: Top five analyst downgrades
03/22/21 Argus
Wendy's cut to Hold at Argus on weak traffic, high debt
FUBO FuboTV
$17.55 /

+1.19 (+7.27%)

05/12/21 Needham
FuboTV again exceeded commitments and guided metrics, says Needham
05/12/21 Evercore ISI
FuboTV's 'clean beat and raise' Q1 report a 'home run,' says Evercore ISI
04/05/21 Evercore ISI
FuboTV assumed with an Outperform at Evercore ISI
03/29/21 Needham
Needham lays out 'bull case' on 'inexpensive' FuboTV shares
EA Electronic Arts
$141.30 /

+0.62 (+0.44%)

05/12/21 Benchmark
Electronic Arts price target raised to $181 from $177 at Benchmark
05/12/21 Barclays
Electronic Arts price target lowered to $142 from $145 at Barclays
05/10/21 Credit Suisse
Electronic Arts price target raised to $167 from $160 at Credit Suisse
04/22/21 Jefferies
Jefferies upgrades Electronic Arts to Buy, sees sentiment as 'too negative'
LITE Lumentum
$82.24 /

+1.335 (+1.65%)

03/26/21 Northland
NeoPhotonics deal 'makes more sense than ever' for Lumentum, says Northland
03/26/21 B. Riley
II-VI upgraded to Buy from Neutral at B. Riley Securities
03/26/21 Raymond James
Lumentum upgraded to Strong Buy from Outperform at Raymond James
03/18/21
Fly Intel: Top five analyst downgrades
TSEM Tower Semiconductor
$27.61 /

+0.01 (+0.04%)

02/18/21 Craig-Hallum
Tower Semiconductor price target raised to $40 from $35 at Craig-Hallum
02/01/21 Craig-Hallum
Tower Semiconductor price target raised to $35 from $27 at Craig-Hallum
01/19/21 Credit Suisse
Tower Semiconductor upgraded to Outperform from Neutral at Credit Suisse
01/18/21 Credit Suisse
Tower Semiconductor upgraded to Outperform from Neutral at Credit Suisse
WWW Wolverine World Wide
$42.75 /

-0.5 (-1.16%)

03/29/21 Baird
Wolverine World Wide price target raised to $44 from $42 at Baird
03/24/21 B. Riley
Wolverine World Wide price target raised to $45 from $39 at B. Riley
03/17/21
Fly Intel: Top five analyst initiations
03/17/21 Williams Capital
Williams Trading starts Wolverine World Wide at Buy with $47 price target
LMND Lemonade
$73.89 /

+2.82 (+3.97%)

04/28/21
Fly Intel: Top five analyst initiations
04/27/21 Credit Suisse
Lemonade assumed with an Underperform at Credit Suisse
04/20/21 JMP Securities
JMP Securities reiterates Outperform on Lemonade amid auto insurance entrance
04/20/21 JMP Securities
Lemonade entrance into auto insurance diversifies offering, says JMP Securities
ARRY Array Technologies
$24.96 /

+0.04 (+0.16%)

05/12/21 Piper Sandler
Array Technologies downgraded to Neutral from Overweight at Piper Sandler
05/12/21 Barclays
Array Technologies downgraded to Underweight from Overweight at Barclays
05/12/21 Roth Capital
Array Technologies downgraded to Neutral from Buy at Roth Capital
04/22/21 Barclays
Shoals Technologies downgraded to Equal Weight from Overweight at Barclays
GO Grocery Outlet
$40.62 /

-0.7 (-1.69%)

05/12/21 Craig-Hallum
Grocery Outlet downgraded to Hold at Craig-Hallum
05/12/21 Craig-Hallum
Grocery Outlet downgraded to Hold from Buy at Craig-Hallum
05/12/21 Deutsche Bank
Grocery Outlet downgraded on market share concerns at Deutsche Bank
05/12/21 Deutsche Bank
Grocery Outlet downgraded to Hold from Buy at Deutsche Bank
AMRN Amarin
$4.62 /

+0.02 (+0.43%)

05/12/21 Goldman Sachs
Amarin downgraded to Sell from Neutral at Goldman Sachs
04/29/21 Piper Sandler
Piper continues to see 'immense market opportunity' for Amarin in EU
04/12/21 Piper Sandler
New CEO at Amarin to facilitate continued growth, says Piper Sandler
04/06/21 Piper Sandler
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
WWW Wolverine World Wide
$42.75 /

-0.5 (-1.16%)

WEN Wendy's
$22.81 /

+0.08 (+0.35%)

TSEM Tower Semiconductor
$27.61 /

+0.01 (+0.04%)

LMND Lemonade
$73.89 /

+2.82 (+3.97%)

LITE Lumentum
$82.24 /

+1.335 (+1.65%)

LHDX Lucira Health
$5.10 /

+0.555 (+12.21%)

GO Grocery Outlet
$40.62 /

-0.7 (-1.69%)

FUBO FuboTV
$17.55 /

+1.19 (+7.27%)

EA Electronic Arts
$141.30 /

+0.62 (+0.44%)

DT Dynatrace
$45.44 /

+0.035 (+0.08%)

ARRY Array Technologies
$24.96 /

+0.04 (+0.16%)

AMRN Amarin
$4.62 /

+0.02 (+0.43%)

  • 19
    Mar
  • 05
    Feb
  • 14
    Jan
  • 30
    Dec
  • 09
    Dec
  • 03
    Dec
  • 15
    Oct
  • 08
    Oct
  • 13
    Aug
  • 03
    Aug
  • 02
    Jul
  • 03
    Jun
WWW Wolverine World Wide
$42.75 /

-0.5 (-1.16%)

WEN Wendy's
$22.81 /

+0.08 (+0.35%)

LMND Lemonade
$73.89 /

+2.82 (+3.97%)

LITE Lumentum
$82.24 /

+1.335 (+1.65%)

EYES Second Sight
$4.97 /

-0.185 (-3.59%)

EA Electronic Arts
$141.30 /

+0.62 (+0.44%)

WEN Wendy's
$22.81 /

+0.08 (+0.35%)

TSEM Tower Semiconductor
$27.61 /

+0.01 (+0.04%)

LMND Lemonade
$73.89 /

+2.82 (+3.97%)

LITE Lumentum
$82.24 /

+1.335 (+1.65%)

LHDX Lucira Health
$5.10 /

+0.555 (+12.21%)

GO Grocery Outlet
$40.62 /

-0.7 (-1.69%)

FUBO FuboTV
$17.55 /

+1.19 (+7.27%)

EYES Second Sight
$4.97 /

-0.185 (-3.59%)

EA Electronic Arts
$141.30 /

+0.62 (+0.44%)

DT Dynatrace
$45.44 /

+0.035 (+0.08%)

ARRY Array Technologies
$24.96 /

+0.04 (+0.16%)

AMRN Amarin
$4.62 /

+0.02 (+0.43%)

TSEM Tower Semiconductor
$27.61 /

+0.01 (+0.04%)

LMND Lemonade
$73.89 /

+2.82 (+3.97%)

LITE Lumentum
$82.24 /

+1.335 (+1.65%)

LHDX Lucira Health
$5.10 /

+0.555 (+12.21%)

FUBO FuboTV
$17.55 /

+1.19 (+7.27%)

EYES Second Sight
$4.97 /

-0.185 (-3.59%)

EA Electronic Arts
$141.30 /

+0.62 (+0.44%)

AMRN Amarin
$4.62 /

+0.02 (+0.43%)

Downgrade
Amarin downgraded to Sell from Neutral at Goldman Sachs » 04:53
05/12/21
05/12
04:53
05/12/21
04:53
AMRN

Amarin

$4.62 /

+0.02 (+0.43%)

Goldman Sachs analyst…

Goldman Sachs analyst Paul Choi downgraded Amarin to Sell from Neutral with a price target of $5, down from $6. The stock in premarket trading is down 3% to $4.45. Generic entrants in the U.S. will limit Vascepa's growth ahead of the European launch, Choi tells investors in a research note. The analyst sees a "clear need" for Amarin to diversify away from Vascepa. Consensus estimates call for year-over-year growth in Vascepa sales despite the steady utilization of Hikma's generic Vascepa and the pending launch of Dr. Reddy's own generic product, says Choi. He expects both to increasingly erode Vascepa's market share in 2021 and beyond. Physicians overwhelmingly indicate plans to prescribe generic products, particularly given coverage and cost challenges associated with branded Vascepa, says the analyst, citing his conversations with them. Choi sees "increasing urgency" for Amarin to engage in more active business development to develop the pipeline that can be commercial-ready ahead of European loss of exclusivity in the early 2030s.

ShowHide Related Items >><<
AMRN Amarin
$4.62 /

+0.02 (+0.43%)

AMRN Amarin
$4.62 /

+0.02 (+0.43%)

04/29/21 Piper Sandler
Piper continues to see 'immense market opportunity' for Amarin in EU
04/12/21 Piper Sandler
New CEO at Amarin to facilitate continued growth, says Piper Sandler
04/06/21 Piper Sandler
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
02/25/21 Piper Sandler
Amarin to have strong execution year ahead, says Piper Sandler
AMRN Amarin
$4.62 /

+0.02 (+0.43%)

AMRN Amarin
$4.62 /

+0.02 (+0.43%)

AMRN Amarin
$4.62 /

+0.02 (+0.43%)

Over a week ago
Recommendations
Piper continues to see 'immense market opportunity' for Amarin in EU » 10:32
04/29/21
04/29
10:32
04/29/21
10:32
AMRN

Amarin

$5.43 /

+0.24 (+4.62%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi said she continues to be impressed by Amarin's commercial preparations in the EU and while "the Street is impatient for EU launch," she emphasized that it will take time to obtain market access and negotiate pricing. The analyst, who continues to believe the EU "represents an immense market opportunity" and expresses conviction in Amarin's ability to execute, keeps an Overweight rating and $19 price target on the shares following the company's Q1 report.

ShowHide Related Items >><<
AMRN Amarin
$5.43 /

+0.24 (+4.62%)

AMRN Amarin
$5.43 /

+0.24 (+4.62%)

04/12/21 Piper Sandler
New CEO at Amarin to facilitate continued growth, says Piper Sandler
04/06/21 Piper Sandler
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
02/25/21 Piper Sandler
Amarin to have strong execution year ahead, says Piper Sandler
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
AMRN Amarin
$5.43 /

+0.24 (+4.62%)

AMRN Amarin
$5.43 /

+0.24 (+4.62%)

AMRN Amarin
$5.43 /

+0.24 (+4.62%)

AMRN Amarin
$5.43 /

+0.24 (+4.62%)

Earnings
Amarin reports Q1 non-GAAP EPS 3c, consensus (5c) » 06:19
04/29/21
04/29
06:19
04/29/21
06:19
AMRN

Amarin

$5.19 /

-0.01 (-0.19%)

Reports Q1 revenue…

Reports Q1 revenue $142.2M, consensus $147.1M. "Results in Q1 reflect a mixture of positive accomplishments and continued headwinds, particularly from COVID-19, the effects of which continued to be more persistent than was hoped," stated CEO John Thero. "A clear highlight of the quarter was the broad label for VAZKEPA which is now authorized for marketing in Europe. The opportunity for VAZKEPA in Europe is large and our team in Europe is making tremendous progress. In the United States, while we ended Q1 with some early signs of potential recovery from the effects of COVID-19, such as increased rates of patients new to the brand and more prescribers of VASCEPA, such signs are based on limited data, inconsistent, and vary by geography. (...) As we witness greater evidence that the effects of COVID-19 are receding, we plan to increase what we believe to be our most cost-effective marketing initiatives to continue the launch of this important product for the cardiovascular risk reduction indication that we pulled-back due to COVID-19".

ShowHide Related Items >><<
AMRN Amarin
$5.19 /

-0.01 (-0.19%)

AMRN Amarin
$5.19 /

-0.01 (-0.19%)

04/12/21 Piper Sandler
New CEO at Amarin to facilitate continued growth, says Piper Sandler
04/06/21 Piper Sandler
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
02/25/21 Piper Sandler
Amarin to have strong execution year ahead, says Piper Sandler
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
AMRN Amarin
$5.19 /

-0.01 (-0.19%)

AMRN Amarin
$5.19 /

-0.01 (-0.19%)

AMRN Amarin
$5.19 /

-0.01 (-0.19%)

AMRN Amarin
$5.19 /

-0.01 (-0.19%)

Hot Stocks
Amarin announces Great Britain marketing authorization for Vazkepa from MHRA » 10:57
04/22/21
04/22
10:57
04/22/21
10:57
AMRN

Amarin

$5.06 /

-0.015 (-0.30%)

Amarin Corporation plc…

Amarin Corporation plc announced that the Medicines and Healthcare Products Regulatory Agency, or MHRA, has granted a Marketing Authorization for Vazkepa as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides and either established cardiovascular disease or diabetes, and at least one additional cardiovascular risk factor. "The Great Britain Marketing Authorization for Vazkepa applies to England, Scotland and Wales. Under the Brexit Northern Ireland agreement, the European centralized marketing authorization for the European Union covers Northern Ireland," Amarin said.

ShowHide Related Items >><<
AMRN Amarin
$5.06 /

-0.015 (-0.30%)

AMRN Amarin
$5.06 /

-0.015 (-0.30%)

04/12/21 Piper Sandler
New CEO at Amarin to facilitate continued growth, says Piper Sandler
04/06/21 Piper Sandler
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
02/25/21 Piper Sandler
Amarin to have strong execution year ahead, says Piper Sandler
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
AMRN Amarin
$5.06 /

-0.015 (-0.30%)

AMRN Amarin
$5.06 /

-0.015 (-0.30%)

AMRN Amarin
$5.06 /

-0.015 (-0.30%)

AMRN Amarin
$5.06 /

-0.015 (-0.30%)

Hot Stocks
Amarin presents new analyses of EVAPORATE study » 16:06
04/18/21
04/18
16:06
04/18/21
16:06
AMRN

Amarin

$5.02 /

+0.01 (+0.20%)

Amarin announced that…

Amarin announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking Science at European Society of Cardiology Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology, on April 17. As previously reported and published in the European Heart Journal, VASCEPA demonstrated significant, 17% regression of low attenuation plaque volume on multidetector computed tomography compared with placebo over 18 months. The Effect of Icosapent Ethyl on Changes in Coronary Plaque Morphology: EVAPORATE analyses presented at ESC Preventive Cardiology 2021 demonstrated that with administration of 4 g/day of VASCEPA on top of statin therapy, there was an observed change in plaque stability occurring at 9 months and sustained through 18 months. Of the 80 patients that were enrolled in the randomized, double-blind, placebo-controlled EVAPORATE trial, 55 patients had images that were able to be utilized for the histology-validated software. The EVAPORATE plaque morphology study used ElucidVivo, the first FDA-cleared analysis for specific tissue characterization using histopathologic correlates to assess plaque morphology characteristics, including Lipid Rich Necrotic Core, fibrous cap thickness, and intraplaque hemorrhage. Whereas with placebo LRNC increased and cap thickness decreased, both indicative of moving to a less stable phenotype, with icosapent ethyl there was a measured LRNC decrease and cap thickness increase, indicative of moving to a more stable phenotype. The primary limitation of this single coronary plaque study as identified by its investigators is its small sample size. More study is needed to more fully understand the effects of VASCEPA on coronary plaque to determine the relationship, if any, of such plaque effects on cardiovascular risk reduction.

ShowHide Related Items >><<
AMRN Amarin
$5.02 /

+0.01 (+0.20%)

AMRN Amarin
$5.02 /

+0.01 (+0.20%)

04/12/21 Piper Sandler
New CEO at Amarin to facilitate continued growth, says Piper Sandler
04/06/21 Piper Sandler
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
02/25/21 Piper Sandler
Amarin to have strong execution year ahead, says Piper Sandler
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
AMRN Amarin
$5.02 /

+0.01 (+0.20%)

AMRN Amarin
$5.02 /

+0.01 (+0.20%)

AMRN Amarin
$5.02 /

+0.01 (+0.20%)

AMRN Amarin
$5.02 /

+0.01 (+0.20%)

Over a month ago
Recommendations
New CEO at Amarin to facilitate continued growth, says Piper Sandler » 20:53
04/12/21
04/12
20:53
04/12/21
20:53
AMRN

Amarin

$5.85 /

-0.09 (-1.52%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi keeps her Overweight rating and $19 price target on Amarin after the company announced that Karim Mikhail would succeed John Thero as CEO later this year. The Street was surprised by the announcement, the analyst tells investors in a research note, but she believes that his deep commercial expertise will facilitate Amarin's continued growth, especially ahead of VAZKEPA's E.U. launch in Q3 of this year.

ShowHide Related Items >><<
AMRN Amarin
$5.85 /

-0.09 (-1.52%)

AMRN Amarin
$5.85 /

-0.09 (-1.52%)

04/06/21 Piper Sandler
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
02/25/21 Piper Sandler
Amarin to have strong execution year ahead, says Piper Sandler
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
01/29/21 Piper Sandler
Amarin's EU approval 'guaranteed' after CHMP nod, says Piper Sandler
AMRN Amarin
$5.85 /

-0.09 (-1.52%)

AMRN Amarin
$5.85 /

-0.09 (-1.52%)

AMRN Amarin
$5.85 /

-0.09 (-1.52%)

AMRN Amarin
$5.85 /

-0.09 (-1.52%)

Hot Stocks
Amarin CEO John Thero to retire, Karim Mikhail to succeed » 16:32
04/12/21
04/12
16:32
04/12/21
16:32
AMRN

Amarin

$5.85 /

-0.09 (-1.52%)

Amarin announced that…

Amarin announced that John Thero has informed the board of directors of his plan to retire as president and CEO, effective August 1. He will also step down from the board at that time. The board has appointed Karim Mikhail, Amarin's senior vice president and head of commercial for Europe, to succeed Thero as the company's next president and CEO. Mikhail will join the board upon his effective date. Thero will continue to provide his guidance and expertise to the company in an advisory capacity through the end of 2021. Mikhail joined Amarin in 2020 from THEODON, a global commercial strategy consultancy he founded in 2018.

ShowHide Related Items >><<
AMRN Amarin
$5.85 /

-0.09 (-1.52%)

AMRN Amarin
$5.85 /

-0.09 (-1.52%)

04/06/21 Piper Sandler
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
02/25/21 Piper Sandler
Amarin to have strong execution year ahead, says Piper Sandler
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
01/29/21 Piper Sandler
Amarin's EU approval 'guaranteed' after CHMP nod, says Piper Sandler
AMRN Amarin
$5.85 /

-0.09 (-1.52%)

AMRN Amarin
$5.85 /

-0.09 (-1.52%)

AMRN Amarin
$5.85 /

-0.09 (-1.52%)

AMRN Amarin
$5.85 /

-0.09 (-1.52%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.